Agardh C D, Rasmussen F, Nilsson-Ehle P, Gustafson A
Urology. 1986 Dec;28(6):469-71. doi: 10.1016/0090-4295(86)90145-7.
Treatment of prostatic carcinoma with estrogens is accompanied by an increased risk for thromboembolic and cardiovascular complications. The underlying mechanisms are still unknown. Patients treated with diethylstilbestrol (DES) were compared with patients given no estrogen treatment regarding factors (platelet aggregation in vitro and plasma lipoproteins) that have been suggested to contribute to increased thrombogenesis and cardiovascular risk. The results do not show any increase in in vitro platelet aggregation in patients treated with DES compared with those given no treatment. This indicates that hyperaggregability does not contribute to the increased incidence in thromboembolic events seen in DES-treated patients. This is in contrast to the increased platelet aggregation previously described in patients treated with polyestradiolphosphate + etinylestradiol. The changes in plasma lipoproteins observed during DES-treatment are generally considered beneficial from an atherogenic point of view and do not appear to cause the elevated incidence of cardiovascular disease in these patients.
用雌激素治疗前列腺癌会增加血栓栓塞和心血管并发症的风险。其潜在机制尚不清楚。将接受己烯雌酚（DES）治疗的患者与未接受雌激素治疗的患者在一些被认为会导致血栓形成增加和心血管风险的因素（体外血小板聚集和血浆脂蛋白）方面进行了比较。结果显示，与未接受治疗的患者相比，接受DES治疗的患者体外血小板聚集没有增加。这表明血小板高聚集性并非DES治疗患者血栓栓塞事件发生率增加的原因。这与先前描述的接受多聚雌二醇磷酸酯+炔雌醇治疗的患者血小板聚集增加的情况形成对比。从动脉粥样硬化的角度来看，DES治疗期间观察到的血浆脂蛋白变化通常被认为是有益的，而且似乎不会导致这些患者心血管疾病发病率升高。
